| Title |
Effects of Depression and Serotonergic Antidepressants on Bone: Mechanisms and Implications for the Treatment of Depression
|
|---|---|
| Published in |
Drugs & Aging, November 2015
|
| DOI | 10.1007/s40266-015-0323-4 |
| Pubmed ID | |
| Authors |
Brisa S. Fernandes, Jason M. Hodge, Julie A. Pasco, Michael Berk, Lana J. Williams |
| Abstract |
Osteoporosis is a chronic skeletal disease marked by microarchitectural deterioration of the bone matrix and depletion of bone mineral density (BMD), with a consequent increased risk for fragility fractures. It has been frequently associated with depression, which is also a chronic and debilitating disorder with high prevalence. Selective serotonin reuptake inhibitors (SSRIs), first-line agents in the pharmacological treatment of mood and anxiety disorders, have also been shown to negatively affect bone metabolism. SSRIs are the most prescribed antidepressants worldwide and a large number of persons at risk of developing osteoporosis, including older patients, will receive these antidepressants. Therefore, a proper musculoskeletal evaluation of individuals who are being targeted for or using SSRIs is a priority. The aim of this article is to review the evidence regarding the effects of depression and serotonergic antidepressants on bone and its implications for clinical care. |
Mendeley readers
The data shown below were compiled from readership statistics for 59 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 2% |
| Unknown | 58 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 11 | 19% |
| Student > Bachelor | 9 | 15% |
| Researcher | 8 | 14% |
| Student > Doctoral Student | 5 | 8% |
| Student > Ph. D. Student | 3 | 5% |
| Other | 5 | 8% |
| Unknown | 18 | 31% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 18 | 31% |
| Nursing and Health Professions | 4 | 7% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 5% |
| Agricultural and Biological Sciences | 3 | 5% |
| Psychology | 3 | 5% |
| Other | 9 | 15% |
| Unknown | 19 | 32% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 October 2020.
All research outputs
#7,468,612
of 22,832,057 outputs
Outputs from Drugs & Aging
#520
of 1,195 outputs
Outputs of similar age
#96,811
of 285,879 outputs
Outputs of similar age from Drugs & Aging
#10
of 22 outputs
Altmetric has tracked 22,832,057 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,195 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.6. This one is in the 32nd percentile – i.e., 32% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 285,879 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 57% of its contemporaries.
We're also able to compare this research output to 22 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 50% of its contemporaries.